Pfizer (PFE), Medivation (MDVN) Report Dimebon Does Not Report Statistically Significant Results in Phase 3 HORIZON
Get Alerts PFE Hot Sheet
Price: $27.75 -0.11%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -55.3%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -55.3%
Join SI Premium – FREE
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (Nasdaq: MDVN) report the following results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease.
Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).
Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function (p=0.84).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
- Altimmune (ALT) Announces Lean Mass Preservation Data for Pemvidutide
- PayPal (PYPL) Appoint Carmine Di Sibio to its Board
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!